- Home
- ANEB vs RNTX Comparison
ANEB vs RNTX Comparison
Compare ANEB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- RNTX
- Stock Information
- Founded
- ANEB 2020
- RNTX 2001
- Country
- ANEB United States
- RNTX United States
- Employees
- ANEB N/A
- RNTX N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- ANEB Health Care
- RNTX Health Care
- Exchange
- ANEB Nasdaq
- RNTX Nasdaq
- Market Cap
- ANEB 39.0M
- RNTX 40.3M
- IPO Year
- ANEB 2021
- RNTX N/A
- Fundamental
- Price
- ANEB $1.66
- RNTX $1.45
- Analyst Decision
- ANEB Strong Buy
- RNTX
- Analyst Count
- ANEB 2
- RNTX 0
- Target Price
- ANEB $5.50
- RNTX N/A
- AVG Volume (30 Days)
- ANEB 21.1K
- RNTX 37.5K
- Earning Date
- ANEB 05-13-2025
- RNTX 08-13-2025
- Dividend Yield
- ANEB N/A
- RNTX N/A
- EPS Growth
- ANEB N/A
- RNTX N/A
- EPS
- ANEB N/A
- RNTX N/A
- Revenue
- ANEB N/A
- RNTX N/A
- Revenue This Year
- ANEB N/A
- RNTX N/A
- Revenue Next Year
- ANEB N/A
- RNTX N/A
- P/E Ratio
- ANEB N/A
- RNTX N/A
- Revenue Growth
- ANEB N/A
- RNTX N/A
- 52 Week Low
- ANEB $0.80
- RNTX $1.33
- 52 Week High
- ANEB $3.08
- RNTX $4.40
- Technical
- Relative Strength Index (RSI)
- ANEB 59.78
- RNTX N/A
- Support Level
- ANEB $1.57
- RNTX N/A
- Resistance Level
- ANEB $2.00
- RNTX N/A
- Average True Range (ATR)
- ANEB 0.25
- RNTX 0.00
- MACD
- ANEB 0.00
- RNTX 0.00
- Stochastic Oscillator
- ANEB 30.25
- RNTX 0.00
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.